Related Experiment Video
Updated: Jan 18, 2026
Setup of Consumer Wearable Devices for Exposure and Health Monitoring in Population Studies
Published on: February 3, 2023
Metabolic Medications and Youth Hospitalizations for Asthma: A Pre-Post Quasi-Experimental Study
Sixtus Aguree1, Bowen Jiang2, Yash Kalpesh Shah2
1Department of Applied Health Science, Indiana University School of Public Health-Bloomington, Bloomington, IN.
Background:
Obesity and metabolic dysregulation can lead to adverse outcomes in people with asthma. We hypothesized that pharmacological treatment of metabolic conditions in youth with asthma is associated with lowered risk of severe asthma exacerbations.
Research Question:
Is metabolic pharmacotherapy associated with a lower risk of severe asthma exacerbations among children and young adults with metabolic dysregulation?
Study Design And Methods:
This retrospective, quasi-experimental, longitudinal study examined severe asthma exacerbations (those requiring hospitalization or an emergency department [ED] visit) among youth aged 5-25 years with asthma and a history of a metabolic condition (obesity, diabetes, or hypertension). Definitions and diagnoses were based on documented international classification of diseases (ICD) codes. We compared the odds of severe asthma exacerbations before and after the initiation of metabolic pharmocotheraphy using adjusted piecewise generalized linear mixed models.
Results:
The cohort consisted of 783 patients, predominantly female (73.7%), white (71.6%), and non-Hispanic (90.4%). Metformin was the most frequently prescribed metabolic medication (75.4%). Before initiating metabolic pharmocotheraphy, the odds of severe asthma exacerbations increased by 29% per year (OR=1.29, 95%CI = 1.12-1.49). Conversely, following the commencement of metabolic pharmacotherapy, the odds of severe asthma exacerbations decreased by 66% per year (OR=0.34, 95%CI = 0.23-0.50), showing a statistically significant and marked difference between the pre- and post-treatment periods.
Interpretation:
Our findings show that the odds of severe asthma excerbations are substantially lower after the initiation of metabolic pharmacotheraphy, highlighting the positive impact that treatment of metabolic syndromes could have in reducing the risk of severe asthma exacerbations. This underscores the interconnectedness of metabolic and respiratory health and the need for further research into effective treatment strategies for individuals with asthma and obesity-related metabolic conditions.
More Related Videos
14:39Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
Published on: November 4, 2010
08:30Intraperitoneal Glucose Tolerance Test, Measurement of Lung Function, and Fixation of the Lung to Study the Impact of Obesity and Impaired Metabolism on Pulmonary Outcomes
Published on: March 15, 2018
Related Concept Videos
01:30Asthma-IV: Diagnostic and Management
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
01:19Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers work through two distinct mechanisms:
01:26Asthma-II: Pathophysiology and Classification
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
01:29Asthma-I: Introduction
01:24Antiasthma Drugs: Methylxanthines
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...